BTIG analyst Robert Hazlett initiated coverage of MannKind (MNKD) with a Buy rating and $3 price target.
The stock closed Monday down 2c to $1.23.
With the advancements of continuous glucose monitor technologies, tighter glycemic control will become more of a focus, and MannKind's Afrezza "can play a material role," Hazlett tells investors in a research note.
The analyst estimates inhaled insulin Afrezza's peak U.S. sales at greater than $350M. Mannkind's recently revamped management is attempting to energize Afrezza through publications of differentiating data, which can improve acceptance among physicians and patients, helping "solid growth continue," according to Hazlett.
Comments
Log in or sign up to join the conversation.